Delivra Corp., of Toronto, said results of a preclinical study demonstrating the safety and greater bioavailability of transdermal berberine and dihydroberberine for the prevention and treatment of cardiovascular disease related to high cholesterol and triglyceride levels were published in the March 26, 2018, edition of PLOS ONE.